Table 1.

Investigations of effects of L-DOPA treatment on symptoms of anxiety and depression in Parkinson's disease patients.

Reference	Rating Scale	n	Dose of L-DOPA (mg/day)	De novo?	Treatment Duration	Notes
L-DOPA Improves Anxiety and Depression
Fung et al., 2009	PDQ-8a	184	300–800	No	3 months	L-DOPA/carbidopa/entacapone improved mood
Cantello et al., 1986	BDIb	18	780h	No	NA	BDI scores improved during ON phase of treatment
Witt et al., 2006	BDIb	15	915h	No	Acute	Treatment improved BDI and apathy scores during ON phase
Funkiewiez et al., 2006	ARCIc	22	1420h	No	NA	Treatment improved anxiety and well-being during ON phase
Stacy et al., 2010	WOQ-9d	216	NA	No	NA	Treatment improved anxiety and depression during ON phase
L-DOPA Does Not Affect Anxiety and Depression
Kim et al., 2009	NMSSe	23	376h	Yes	3 months	Treatment did not improve anxiety or mood
Marsh & Markham, 1973	MMPIf	27	4440h	Yes	3 and 15 months	Treatment did not change depression scores
L-DOPA Exacerbates Anxiety and Depression
Choi et al., 2000	BDIb	34	560h	Yes	6–28 months	More patients were depressed after onset of treatment
Negre-Pages et al., 2009	HADSg	422	957h	No	NA	Treatment associated with depression
Damasio et al., 1970	BDIb	48	2000–5000h	Yes	>3 months	Treatment associated with exacerbation of depression and psychosis

^aParkinson's Disease Questionnaire (8 question version)

^bBeck Depression Inventory

^cAddiction Research Center Inventory

^dWearing-Off Questionnaire (9 question version)

^eNon-Motor Symptom Subscale

^fMinnesota Multiphasic Personality Inventory

^gHamilton Anxiety and Depression Scale

^hnot methyl ester form

ⁱaverage dose